Gause

This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.

Researchers are evaluating the safety, tolerability, pharmacokinetics, and early effects of the drug RO7656594 in men with advanced or metastatic prostate cancer. This Phase 1 study aims to find the best doses and treatment schedules for RO7656594 to use in future research. Participants will have metastatic prostate adenocarcinoma and have previously received certain hormone therapies or taxane treatments. RO7656594 will be taken orally according to specific doses and schedules determined by the study. The study uses an open-label design with dose escalation and expansion to assess how participants respond to the drug. Treatment continues in cycles, each lasting 28 days, with monitoring for side effects and drug effects. Participants will be closely monitored throughout the study for any adverse events and dose-limiting toxicities from the start of treatment until up to 28 days after the final dose, which may cover about 24 months. Assessments include safety evaluations, pharmacokinetics, and activity of the drug. Eligibility requires good performance status and previous specific cancer treatments, with exclusion criteria including recent other cancer therapies or untreated brain metastases.